Hepatitis B Surface Antibody, Quantitative

Methodology: 
Immunochemiluminometric assay (ICMA)
Performed: 
Monday - Friday
Use: 
Hepatitis B surface antibody (anti-HBs) level can be measured to determine if vaccination is needed. Following a vaccination regimen, anti-HBs can be measured to determine if protective immunity has been achieved.
 

Limitations

The presence of anti-HBs is not an absolute indicator of resolved hepatitis infection nor of protection from future infection. Since there are different serologic subtypes of hepatitis B virus, it is possible (and has been reported) for a patient to have antibody to one surface antigen type and to be acutely infected with a virus of a different subtype. Thus, a patient may have coexisting HBsAG and anti-HBs. Transfused individuals or hemophiliacs receiving plasma components may give false-positive tests for antibody to hepatitis B surface antigen.
Specimen Requirements: 

Type: Serum or plasma

Container/Tube: Red-top tube, gel-barrier tube or lavender-top tube (EDTA)
  • If a tube other than a gel-barrier tube is used, transfer the separated serum to a plastic transport tube.

Sample Volume: 1 mL

Minimum Volume: 0.5 mL (Repeat testing is not possible with this specimen volume.)

Storage: Refrigerate specimens immediately after collection.

Stability (collection to time of analysis/testing):
  • Ambient: 14 days
  • Refrigerated: 14 days
  • Frozen: 14 days
  • Freeze/Thaw Cycles: Stable (x 3)
Rejection Criteria:
  • Non-EDTA plasma specimen
  • PST gel-barrier tube
Reference Values: 

Reference Intervals

  • Inconsistent with immunity: 0.0 − 9.9 mIU/mL 
     
  • Consistent with immunity: > 9.9 mIU/mL
CPT Code (s): 
86317
Notes: 

UFHPL Test #: 68105

UFHPL Epic order code: LAB21047203

References

Test Directory